Target has announced it will reduce bonuses for salaried employees due to weak consumer spending and inflationary pressures.
Category: wegovy
Auto Added by WPeMatico
Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup
Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has filed for Chapter 11 bankruptcy protection with CEO Anne Wojcicki stepping down to help with a sale. And the U.S. Department of Health and Human Services (HHS)…
- Wegovy sales took a hit this year. Novo’s CEO blames off-brand competition
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma giant’s CEO Lars Fruergaard Jørgensen.